MOVANTIK
Peaknaloxegol oxalate
NDAORALTABLET
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
MOVANTIK (naloxegol oxalate) is mu-opioid receptor. Approved for opioid-induced constipation (oic) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer, its treatment. First approved in 2014.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOVANTIK (naloxegol oxalate) is an oral, peripherally-acting mu-opioid receptor antagonist approved for opioid-induced constipation (OIC) in adults with chronic non-cancer pain. It is a PEGylated derivative of naloxone that blocks opioid effects in the gastrointestinal tract while preserving central analgesic effects. The PEG moiety and P-glycoprotein substrate properties minimize blood-brain barrier penetration, preventing interference with opioid pain relief.
$0.027BPart D
Peak5.5 years to LOEProduct is at peak lifecycle with established market penetration; commercial team focus is on maintaining market share as LOE approaches in 5.5 years.
Mechanism of Action
mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues, such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.